Published in Pharma Investments, Ventures and Law Weekly, November 5th, 2006
This trend article about Stanford University, U.S. is an immediate alert from LawRx to identify developing directions of research.
Study 1: Erythropoietin (Epo) levels rise when vascular endothelial growth factor (VEGF) is blocked.
"VEGF exerts crucial functions during pathological angiogenesis and normal physiology. We observed increased hematocrit (60-75%) after high-grade inhibition of VEGF by diverse methods, including adenoviral expression of soluble VEGF receptor (VEGFR) ectodomains, recombinant VEGF Trap protein and the VEGFR2-selective antibody DC101,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.